Showing 5581-5590 of 10175 results for "".
- Melasma Clinical Trials Show Advancements in Inclusive Representationhttps://practicaldermatology.com/news/melasma-clinical-trials-show-advancements-inclusive-representation/2468760/A new analysis of melasma clinical trials indicates progress toward inclusivity, with broad gender, racial, and Fitzpatrick skin type (FST) representation. Researchers publishing in the Journal of Drugs in Dermatology analyzed melasma clinical trials listed on ClinicalTrials.gov,
- Psoriasis Linked with Education, Mood Disorders: Studyhttps://practicaldermatology.com/news/psoriasis-tied-education-and-mood-disorders-study/2468759/A new genetic study has identified six previously unreported loci associated with psoriasis, emphasizing its genetic complexity and links to socioeconomic and mental health factors. The analysis included data from 925,649 individuals across the FinnGen, Estonian Biobank, and UK Biobank, ma
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl
- GW SMHS Teledermatology Program Receives Renewed Fundinghttps://practicaldermatology.com/news/gw-smhs-teledermatology-program-receives-renewed-funding/2468756/The George Washington University School of Medicine and Health Sciences Department of Dermatology, in collaboration with the Pennsylvania Avenue Baptist Church and the National Psoriasis Foundation (NPF), announced a renewed funding commitment of $350,000 from Johnson & Johnson in support of
- Report: Global Atopic Dermatitis Market Poised for Rapid Expansionhttps://practicaldermatology.com/news/report-global-atopic-dermatitis-market-poised-rapid-expansion/2468755/The atopic dermatitis (AD) market is forecasted to grow from $5.3 billion in 2021 to $22.6 billion by 2031, with a compound annual growth rate (CAGR) of 15.1%, according to a new report. North America as the current market leader, according to a press release from Allied Market Research,
- Study: Cutaneous Lupus Linked With Elevated Cardiovascular Disease Riskhttps://practicaldermatology.com/news/study-cutaneous-lupus-linked-elevated-cardiovascular-disease-risk/2468723/Patients with cutaneous lupus erythematosus (CLE) face an elevated risk of atherosclerotic cardiovascular disease (ASCVD), comparable to that seen in systemic lupus erythematosus (SLE), according to a new study. Authors of the retrospective cohort study analyzed health records of 8,138 pat
- Almirall Announces Scientific Research Hub at R&D Centerhttps://practicaldermatology.com/news/almirall-announces-scientific-research-hub-rd-center/2468710/Almirall announced the launch of “The Hive,” a novel scientific research hub located at its R&D center in Barcelona, Spain. According to a press release, the Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s
- Study Highlights Gaps in Fitzpatrick Skin Type Determinationhttps://practicaldermatology.com/news/study-highlights-gaps-fitzpatrick-skin-type-determination/2468709/New research published in The Journal of Clinical and Aesthetic Dermatology evaluated concordance between self-assessed and provider-determined Fitzpatrick skin types (FSTs). Study researchers conducted the analysis of 472 patients attending a dermatology practice and included dat
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286